← All trials
NCT05094414
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Apr 30, 2022
- First posted
- Oct 26, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 30
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tzu Chi UniversityLead sponsor
- Government of TaiwanCollaborator
- Hualien Tzu Chi General HospitalReponsible party - principal investigator
- Hualien Tzu Chi General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.